Abemaciclib for MBC Patients: Striking the Right Balance

Dear Dr. Renukaprasad A R, Breast cancer is the most common malignancy among women. Cyclin-dependent kinase (CDK) 4/6 proteins promote breast tumor growth and lead to metastatic breast cancer (MBC). Abemaciclib inhibits CDK4/6 proteins and causes cell arrest, subsequently preventing tumor growth. To learn more about the role of abemaciclib in MBC patients, participate in an interactive session with the international experts in oncology on the 27th of October 2022 at 4:30 and 8:30 PM IST. Session highlights: Recent advancements in the use of aromatase inhibitors (Als) and CDK 4 and 6 inhibitors in the first-line setting   Clinical case discussion on managing patients with hormone receptor-positive (HR+) human epidermal growth factor receptor-negative (HER2-) MBC Q&A with the experts I'm Interested   Docplexus is one of the world's Largest online communities Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*